MovDisordV3, PubMed, Corpus, bibRecord, 001E60

The management of tics.

Identifieur interne : 001E60 ( PubMed/Corpus ); précédent : 001E59; suivant : 001E61

The management of tics.

Auteurs : David Shprecher ; Roger Kurlan

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.

RBID : pubmed:19170198

English descriptors

KwdEn :
- Adolescent, Adrenergic alpha-Agonists (therapeutic use), Adult, Antipsychotic Agents (therapeutic use), Attention Deficit Disorder with Hyperactivity (complications), Attention Deficit Disorder with Hyperactivity (drug therapy), Behavior Therapy, Botulinum Toxins, Type A (therapeutic use), Brain Diseases (complications), Child, Combined Modality Therapy, Deep Brain Stimulation, Diagnosis, Differential, Disease Management, Dopamine Agents (therapeutic use), Drug Therapy, Combination, Humans, Mental Disorders (complications), Obsessive-Compulsive Disorder (complications), Obsessive-Compulsive Disorder (drug therapy), Patient Education as Topic, Stereotypic Movement Disorder (diagnosis), Tics (diagnosis), Tics (drug therapy), Tics (etiology), Tics (physiopathology), Tics (therapy).
MESH :
- chemical , therapeutic use : Adrenergic alpha-Agonists, Antipsychotic Agents, Botulinum Toxins, Type A, Dopamine Agents.
- complications : Attention Deficit Disorder with Hyperactivity, Brain Diseases, Mental Disorders, Obsessive-Compulsive Disorder.
- diagnosis : Stereotypic Movement Disorder, Tics.
- drug therapy : Attention Deficit Disorder with Hyperactivity, Obsessive-Compulsive Disorder, Tics.
- etiology : Tics.
- physiopathology : Tics.
- therapy : Tics.
- Adolescent, Adult, Behavior Therapy, Child, Combined Modality Therapy, Deep Brain Stimulation, Diagnosis, Differential, Disease Management, Drug Therapy, Combination, Humans, Patient Education as Topic.

Abstract

A tic is a stereotyped repetitive involuntary movement or sound, frequently preceded by premonitory sensations or urges. Most tic disorders are genetic or idiopathic in nature, possibly due to a developmental failure of inhibitory function within frontal-subcortical circuits modulating volitional movements. Currently available oral medications can reduce the severity of tics, but rarely eliminate them. Botulinum toxin injections can be effective if there are a few particularly disabling motor tics. Deep brain stimulation has been reported to be an effective treatment for the most severe cases, but remains unproven. A comprehensive evaluation accounting for secondary causes, psychosocial factors, and comorbid neuropsychiatric conditions is essential to successful treatment of tic disorders.

DOI: 10.1002/mds.22378
PubMed: 19170198

Links to Exploration step

pubmed:19170198

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The management of tics.</title>
<author><name sortKey="Shprecher, David" sort="Shprecher, David" uniqKey="Shprecher D" first="David" last="Shprecher">David Shprecher</name>
<affiliation><nlm:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="doi">10.1002/mds.22378</idno>
<idno type="RBID">pubmed:19170198</idno>
<idno type="pmid">19170198</idno>
<idno type="wicri:Area/PubMed/Corpus">001E60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The management of tics.</title>
<author><name sortKey="Shprecher, David" sort="Shprecher, David" uniqKey="Shprecher D" first="David" last="Shprecher">David Shprecher</name>
<affiliation><nlm:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adrenergic alpha-Agonists (therapeutic use)</term>
<term>Adult</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Attention Deficit Disorder with Hyperactivity (complications)</term>
<term>Attention Deficit Disorder with Hyperactivity (drug therapy)</term>
<term>Behavior Therapy</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Brain Diseases (complications)</term>
<term>Child</term>
<term>Combined Modality Therapy</term>
<term>Deep Brain Stimulation</term>
<term>Diagnosis, Differential</term>
<term>Disease Management</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Mental Disorders (complications)</term>
<term>Obsessive-Compulsive Disorder (complications)</term>
<term>Obsessive-Compulsive Disorder (drug therapy)</term>
<term>Patient Education as Topic</term>
<term>Stereotypic Movement Disorder (diagnosis)</term>
<term>Tics (diagnosis)</term>
<term>Tics (drug therapy)</term>
<term>Tics (etiology)</term>
<term>Tics (physiopathology)</term>
<term>Tics (therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Agonists</term>
<term>Antipsychotic Agents</term>
<term>Botulinum Toxins, Type A</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Attention Deficit Disorder with Hyperactivity</term>
<term>Brain Diseases</term>
<term>Mental Disorders</term>
<term>Obsessive-Compulsive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Stereotypic Movement Disorder</term>
<term>Tics</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Attention Deficit Disorder with Hyperactivity</term>
<term>Obsessive-Compulsive Disorder</term>
<term>Tics</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tics</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Tics</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Tics</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Behavior Therapy</term>
<term>Child</term>
<term>Combined Modality Therapy</term>
<term>Deep Brain Stimulation</term>
<term>Diagnosis, Differential</term>
<term>Disease Management</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Patient Education as Topic</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A tic is a stereotyped repetitive involuntary movement or sound, frequently preceded by premonitory sensations or urges. Most tic disorders are genetic or idiopathic in nature, possibly due to a developmental failure of inhibitory function within frontal-subcortical circuits modulating volitional movements. Currently available oral medications can reduce the severity of tics, but rarely eliminate them. Botulinum toxin injections can be effective if there are a few particularly disabling motor tics. Deep brain stimulation has been reported to be an effective treatment for the most severe cases, but remains unproven. A comprehensive evaluation accounting for secondary causes, psychosocial factors, and comorbid neuropsychiatric conditions is essential to successful treatment of tic disorders.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19170198</PMID>
<DateCreated><Year>2009</Year>
<Month>02</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>06</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>24</Volume>
<Issue>1</Issue>
<PubDate><Year>2009</Year>
<Month>Jan</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>The management of tics.</ArticleTitle>
<Pagination><MedlinePgn>15-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22378</ELocationID>
<Abstract><AbstractText>A tic is a stereotyped repetitive involuntary movement or sound, frequently preceded by premonitory sensations or urges. Most tic disorders are genetic or idiopathic in nature, possibly due to a developmental failure of inhibitory function within frontal-subcortical circuits modulating volitional movements. Currently available oral medications can reduce the severity of tics, but rarely eliminate them. Botulinum toxin injections can be effective if there are a few particularly disabling motor tics. Deep brain stimulation has been reported to be an effective treatment for the most severe cases, but remains unproven. A comprehensive evaluation accounting for secondary causes, psychosocial factors, and comorbid neuropsychiatric conditions is essential to successful treatment of tic disorders.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shprecher</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kurlan</LastName>
<ForeName>Roger</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>T32 NS007338</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 NS007338-19</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Dec;18(12):1554-6</RefSource>
<PMID Version="1">14673900</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Psychiatr Scand. 2004 Feb;109(2):140-6</RefSource>
<PMID Version="1">14725596</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Child Adolesc Psychiatry. 2004 Feb;43(2):206-14</RefSource>
<PMID Version="1">14726728</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 2004 Jan 15;130(1):85-95</RefSource>
<PMID Version="1">14972371</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosurgery. 2005 Oct;57(4 Suppl):E403; discussion E403</RefSource>
<PMID Version="1">16234657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Nov;20(11):1496-9</RefSource>
<PMID Version="1">16037913</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Dec 27;65(12):1941-9</RefSource>
<PMID Version="1">16380617</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Pediatr Adolesc Med. 2006 Jan;160(1):65-9</RefSource>
<PMID Version="1">16389213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2000 Jul;247(7):514-20</RefSource>
<PMID Version="1">10993492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Mar 13;56(5):599-604</RefSource>
<PMID Version="1">11245709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Mar 13;56(5):605-10</RefSource>
<PMID Version="1">11245710</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Neurol. 2001 Sep;25(3):190-8</RefSource>
<PMID Version="1">11587872</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Feb 26;58(4):527-36</RefSource>
<PMID Version="1">11865128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 May;17(3):618-20</RefSource>
<PMID Version="1">12112223</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Aug 13;59(3):414-20</RefSource>
<PMID Version="1">12177376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Jul;17(4):735-40</RefSource>
<PMID Version="1">12210863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Jul;17(4):821-5</RefSource>
<PMID Version="1">12210884</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Dec 10;59(11):1789-91</RefSource>
<PMID Version="1">12473773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Feb 25;60(4):606-11</RefSource>
<PMID Version="1">12601100</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2003 Apr;64(4):459-65</RefSource>
<PMID Version="1">12716250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2003 Jun;160(6):1175-7</RefSource>
<PMID Version="1">12777279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Aug 12;61(3):310-5</RefSource>
<PMID Version="1">12913189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2004 May 1;55(9):916-25</RefSource>
<PMID Version="1">15110735</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 May 11;62(9):1626-7</RefSource>
<PMID Version="1">15136698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2004 May-Jun;27(3):101-4</RefSource>
<PMID Version="1">15190229</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res Cogn Brain Res. 2004 Aug;20(3):438-48</RefSource>
<PMID Version="1">15268921</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Oct;19(10):1190-6</RefSource>
<PMID Version="1">15390017</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Autism Child Schizophr. 1973 Jul-Sep;3(3):247-53</RefSource>
<PMID Version="1">4800390</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1976 Mar 29;235(13):1349-51</RefSource>
<PMID Version="1">1061848</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Can J Neurol Sci. 1977 Nov;4(4):279-83</RefSource>
<PMID Version="1">271517</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1982 Mar 26;247(12):1729-31</RefSource>
<PMID Version="1">6950128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1983 Jul;40(7):443-4</RefSource>
<PMID Version="1">6574730</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 1984 Jun;73(6):841-4</RefSource>
<PMID Version="1">6587312</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1986 Nov;143(11):1467-8</RefSource>
<PMID Version="1">3465244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>South Med J. 1988 Sep;81(9):1103-5</RefSource>
<PMID Version="1">3047878</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1989 Mar;50(3):103-4</RefSource>
<PMID Version="1">2925592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1989 Aug;12(4):298-302</RefSource>
<PMID Version="1">2529963</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1990 Feb;13(1):77-83</RefSource>
<PMID Version="1">2306750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1990 Jun;40(6):999-1000</RefSource>
<PMID Version="1">2345623</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 1991 Feb;114 ( Pt 1A):13-49</RefSource>
<PMID Version="1">1998879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1991 Apr;41(4):592-3</RefSource>
<PMID Version="1">1849241</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 1995 Aug 1;38(3):196-7</RefSource>
<PMID Version="1">7578666</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1996 Jul;153(7):965</RefSource>
<PMID Version="1">8659625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1995 Nov;10(6):791-3</RefSource>
<PMID Version="1">8749999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1996 Jul;11(4):431-3</RefSource>
<PMID Version="1">8813224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1996 Nov;11(6):746-8</RefSource>
<PMID Version="1">8914108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1997 Mar;12(2):246-8</RefSource>
<PMID Version="1">9087987</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1997 Apr;54(4):475-83</RefSource>
<PMID Version="1">9109750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurol Clin. 1997 May;15(2):267-75</RefSource>
<PMID Version="1">9115460</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):589-96</RefSource>
<PMID Version="1">9136492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1997 Sep;12(5):776-82</RefSource>
<PMID Version="1">9380066</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1998 Feb;155(2):264-71</RefSource>
<PMID Version="1">9464208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Feb 7;351(9100):418-9</RefSource>
<PMID Version="1">9482302</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1998 May;13(3):617-9</RefSource>
<PMID Version="1">9613771</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 1998 Jun;101(6):E4</RefSource>
<PMID Version="1">9606246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1996 Sep;57(9):407-14</RefSource>
<PMID Version="1">9746449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999 Apr 12;52(6):1191-4</RefSource>
<PMID Version="1">10214742</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1999 Jul;156(7):1122-3</RefSource>
<PMID Version="1">10401479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2005 Mar;4(3):149-59</RefSource>
<PMID Version="1">15721825</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neurophysiol. 2005 Apr;116(4):764-8</RefSource>
<PMID Version="1">15792884</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2005 Apr;66(4):499-503</RefSource>
<PMID Version="1">15816793</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2005 Jun;128(Pt 6):1292-300</RefSource>
<PMID Version="1">15774505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 May 24;64(10):1810-2</RefSource>
<PMID Version="1">15911822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Jun;20(6):714-8</RefSource>
<PMID Version="1">15704204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):992-5</RefSource>
<PMID Version="1">15965209</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Behav Modif. 2005 Sep;29(5):784-99</RefSource>
<PMID Version="1">16046664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Neuropsychopharmacol. 2006 Feb;9(1):95-100</RefSource>
<PMID Version="1">15982444</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Rev Neurother. 2006 Jan;6(1):7-17</RefSource>
<PMID Version="1">16466307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Feb 14;66(3):E12</RefSource>
<PMID Version="1">16476922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Mar;21(3):419-20</RefSource>
<PMID Version="1">16229000</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CNS Neurol Disord Drug Targets. 2006 Feb;5(1):79-97</RefSource>
<PMID Version="1">16613555</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 May;21(5):709-13</RefSource>
<PMID Version="1">16463374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Jul;21(7):944-9</RefSource>
<PMID Version="1">16538618</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Psychopharmacol. 2006 Oct;21(7):447-53</RefSource>
<PMID Version="1">17029306</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Nov;21(11):1966-72</RefSource>
<PMID Version="1">16958131</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jan 9;68(2):159-60</RefSource>
<PMID Version="1">17210901</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Neuropsychopharmacol. 2007 Apr;10(2):245-52</RefSource>
<PMID Version="1">16945163</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):840-8</RefSource>
<PMID Version="1">17581448</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jul 17;69(3):306-9</RefSource>
<PMID Version="1">17636069</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jul 15;22(9):1346-50</RefSource>
<PMID Version="1">17580320</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2007 Jul;68(7):1088-93</RefSource>
<PMID Version="1">17685747</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Neurochir Suppl. 2007;97(Pt 2):215-22</RefSource>
<PMID Version="1">17691307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 May;9(3):369-71</RefSource>
<PMID Version="1">8041384</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neurophysiol. 2007 Oct;118(10):2314-5</RefSource>
<PMID Version="1">17709291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Sep 15;22(12):1764-70</RefSource>
<PMID Version="1">17566124</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosurg. 2007 Nov;107(5):1004-14</RefSource>
<PMID Version="1">17977274</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2007 Nov;64(11):1661-4</RefSource>
<PMID Version="1">17998451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med Clin (Barc). 2007 Nov 3;129(16):632-7</RefSource>
<PMID Version="1">18001678</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2007 Dec;164(12):1914-5</RefSource>
<PMID Version="1">18056252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1992 Aug;49(8):874-6</RefSource>
<PMID Version="1">1355964</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1993 Jan;150(1):98-102</RefSource>
<PMID Version="1">8417589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1993 Apr;8(2):175-8</RefSource>
<PMID Version="1">8474485</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1993 Oct;50(10):1013-6</RefSource>
<PMID Version="1">8215958</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Child Adolesc Psychiatry. 1994 Mar-Apr;33(3):394-9</RefSource>
<PMID Version="1">8169185</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychopharmacol. 1994 Apr;14(2):131-5</RefSource>
<PMID Version="1">8195454</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 May;9(3):347-9</RefSource>
<PMID Version="1">8041378</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dev Med Child Neurol. 2000 Jul;42(7):436-47</RefSource>
<PMID Version="1">10972415</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Mar;123 Pt 3:425-62</RefSource>
<PMID Version="1">10686169</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Mar 28;54(6):1310-5</RefSource>
<PMID Version="1">10746603</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):738-43</RefSource>
<PMID Version="1">10811697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Epilepsia. 2000 Jul;41(7):862-7</RefSource>
<PMID Version="1">10897158</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2000 Jun;247(6):443-6</RefSource>
<PMID Version="1">10929273</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ital J Neurol Sci. 1998 Dec;19(6):383-5</RefSource>
<PMID Version="1">10935835</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Synapse. 2000 Oct;38(1):10-6</RefSource>
<PMID Version="1">10941136</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1995 Sep;152(9):1359-61</RefSource>
<PMID Version="1">7653693</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):136-42</RefSource>
<PMID Version="1">17846115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Feb 15;23(3):438-40</RefSource>
<PMID Version="1">18067182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2008 May;33(6):1239-51</RefSource>
<PMID Version="1">17987065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Pharmacol. 2008 May;73(5):1339-42</RefSource>
<PMID Version="1">18314495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Apr 15;23(5):765-6</RefSource>
<PMID Version="1">18265017</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Schizophr Res. 2008 Apr;101(1-3):295-303</RefSource>
<PMID Version="1">18299188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 May 15;23(7):993-7</RefSource>
<PMID Version="1">18383536</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2008 Jul;65(7):952-7</RefSource>
<PMID Version="1">18625864</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Jul 15;23(9):1300-2</RefSource>
<PMID Version="1">18528896</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001289">Attention Deficit Disorder with Hyperactivity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001521">Behavior Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001927">Brain Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D046690">Deep Brain Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019468">Disease Management</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001523">Mental Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009771">Obsessive-Compulsive Disorder</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010353">Patient Education as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019956">Stereotypic Movement Disorder</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020323">Tics</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>116</NumberOfReferences>
<OtherID Source="NLM">NIHMS97532</OtherID>
<OtherID Source="NLM">PMC2701289</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.22378</ArticleId>
<ArticleId IdType="pubmed">19170198</ArticleId>
<ArticleId IdType="pmc">PMC2701289</ArticleId>
<ArticleId IdType="mid">NIHMS97532</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E60 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E60 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:19170198
   |texte=   The management of tics.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:19170198" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The management of tics.

The management of tics.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki